Breast cancer cell membrane coated drug-loaded nanoparticles as well as preparation method and application thereof

By carrying PLGA nanoparticles that coat breast cancer cell membranes, combined with shRNA targeting RecQ DNA helicase, the systemic toxicity and targeting of chemotherapy drugs are solved, and efficient killing and targeting of breast cancer cells is achieved. Improved orientedness, with high safety and medical transformation prospects.

CN119055613APending Publication Date: 2024-12-03GUIZHOU MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411249285.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Among the existing breast cancer treatment methods, chemotherapeutic drugs such as doxorubicin have problems with systemic toxicity and drug resistance, and PLGA nanoparticles have problems with insufficient targeting and sustained release capabilities in clinically approved intravenous administration preparations.

Method used

The breast cancer cell membrane was coated with drug-loaded nanoparticles. The surface of the PLGA nanoparticles was coated with breast cancer cell membrane by coextrusion, and loaded with doxorubicin hydrochloride and shRNA targeting RecQ DNA helicase to improve the target of the nanoparticles. Tyratic and biocompatibility.

Benefits of technology

It has achieved efficient killing of breast cancer cells, improved the therapeutic effect, significantly improved the targeting of drugs and serum stability, reduced side effects, and had high safety and medical transformation prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055613A_ABST
    Figure CN119055613A_ABST
Patent Text Reader

Abstract

The invention discloses a breast cancer cell membrane coated drug-loaded nanoparticle as well as a preparation method and application thereof. The breast cancer cell membrane coated drug-loaded nanoparticle comprises a drug-loaded nanoparticle and a breast cancer cell membrane coated on the surface of the drug-loaded nanoparticle, wherein the drug-loaded nanoparticles comprise a carrier, doxorubicin hydrochloride loaded on the carrier and a nucleotide sequence of shRNA (short hairpin Ribonucleic Acid) targeting RecQ DNA helicase, and the carrier comprises a polylactic acid-glycollic acid copolymer. The breast cancer cell membrane coated drug-loaded nanoparticles have the characteristics of good targeting property, biocompatibility, serum stability and slow release ability, effective knockdown of target genes, and improvement of the killing effect on tumor cells. Through verification, the breast cancer cell membrane-coated drug-loaded nanoparticles can be used for treating triple negative breast cancer and have relatively high safety, so that the breast cancer cell membrane-coated drug-loaded nanoparticles disclosed by the invention have a good medical transformation prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of targeted anti-tumor drugs, and in particular to breast cancer cell membrane-coated drug-loaded nanoparticles and a preparation method and application thereof. Background Art

[0002] Breast cancer is one of the most common malignant tumors in women, with the highest mortality and morbidity rates. Despite the improvement of people's living standards and the advancement of medical technology, the incidence of breast cancer is still increasing year by year, seriously threatening women's health. The term "triple-negative breast cancer" (TNBC) was first reported in the literature in 2005. TNBC is a subtype of breast cancer with a poor prognosis and fewer treatment options. TNBC is characterized by the lack of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2). Therefore, it cannot be treated by treatments targeting these receptors, such as hormone therapy and HER2 targeted therapy. Traditional treatments for TNBC include chemotherapy, radiotherapy and surgery. Chemotherapy includes drugs such as anthracyclines, taxanes, cisplatin, etc. Among them, doxorubicin (Dox) is a topoisomerase II inhibitor. Dox inserts into DNA, inhibits topoisomerase II binding to DNA and reconnection of broken chains. Although Dox is an effective anticancer agent, it has serious side effects of systemic toxicity and myocardial toxicity as well as drug resistance, especially during long-term treatment. At the same time, patients with residual disease after chemotherapy and surgery have a higher mortality rate and a high postoperative recurrence rate. Therefore, finding new treatment strategies is of great significance for improving the prognosis of TNBC patients.

[0003] In recent years, with the rapid development of tumor molecular biology research, the combined synergistic therapy of chemotherapy drugs and genes has received extensive research and attention. Gene therapy is a revolutionary treatment method that provides a new method for treating previously incurable diseases. It achieves the effect of precision treatment by specifically targeting disease-related genes. Upregulating / downregulating genes responsible for regulating the compensatory mechanisms of cell death and DNA repair makes cells more sensitive to the effects of chemotherapy, thereby ideally leading to the restoration of chemotherapy sensitivity (1). Combining anticancer drugs with other treatments with different mechanisms of action is becoming a promising method for treating drug-resistant cancers. Gene therapy can target specific and effective anticancer resistance genes. Combining with chemotherapy drugs should produce synergistically enhanced treatment results and restore the anticancer effects of the drugs used. Gene therapy uses DNA as an active substance, but can also use RNA, commonly known as RNAi therapy, such as microRNA (miRNA), small interfering RNA (siRNA) and short hairpin RNA (shRNA) are introduced as regulators of target gene expression. This regulation is achieved through the RNA interference (RNAi) mechanism, resulting in the destruction of complementary post-transcriptional mRNA (siRNA) or inhibition of its translation. DNA plasmids are circular double-stranded DNA molecules that are independent of cellular chromosomal DNA. The size of plasmids ranges from a few thousand base pairs to tens of thousands of base pairs. In order to regulate the expression of target genes, exogenous DNA molecules are introduced into host cells to restore the function of target genes, thereby promoting their therapeutic effects. Although RNA therapy has great potential in the treatment of diseases, there are still some shortcomings. Nucleic acid delivery must overcome physiological barriers after systemic administration, including nonspecific interactions with plasma proteins, rapid clearance or premature inactivation in the blood and clearance of RNA from the circulation by the mononuclear phagocyte system (MPS), as well as its poor targeted transport ability. To overcome these shortcomings, co-delivery systems loaded with chemotherapeutic drugs and nucleic acids ensure that they undergo the same body distribution and kinetics, thereby achieving the optimal benefit of the combination.

[0004] RecQ DNA helicases are known as the "caretakers" of the genome and function in multiple pathways to separate the DNA double helix using the energy generated by ATP hydrolysis. This function makes RecQ DNA helicases key players in cell replication, transcription, DNA repair, and maintaining genome integrity and cellular homeostasis. Most mammals have five RecQ DNA helicases: RecQL1, BLM, WRN, RecQL4, and RecQL5. Biallelic loss-of-function pathogenic variants in BLM, WRN, and RECQL4 in humans are associated with rare cancer predisposition syndromes. For example, homozygous loss-of-function mutations in BLM cause Bloom syndrome, which is characterized by premature aging, immune deficiency, and skin lesions.

[0005] Nanotechnology includes the practical application of nanoscience in many fields, including chemistry, biology, engineering and electronics. Among them, nanoparticles are used as drug carriers. As a result, nanomedicine has become a booming science because it can help overcome the limitations of traditional treatments. Poly(lactide-co-glycolideacid) (PLGA) nanoparticles are a biodegradable polymer. Therapies based on PLGA nanoparticles have entered preclinical development or are being used in biomedical research because of their attractive properties of biodegradability, low toxicity, high biocompatibility, easy processing and sustained release. However, PLGA still has obvious defects in clinically approved intravenous formulations. The outstanding problem of unmodified PLGA particles may be the hydrophobic nature of polyester, which leads to the adsorption of serum proteins (i.e., opsonization) and a series of events, which are easily cleared by the reticuloendothelial system (RES) as foreign bodies, ultimately resulting in the release of therapeutic drugs at off-target sites or no release at all. Therefore, it is necessary to optimize or modify the PLGA nanodelivery system to enhance the targeting and sustained release capabilities.

[0006] In view of this, the present invention is proposed. Summary of the invention

[0007] The purpose of the present invention is to provide a breast cancer cell membrane-coated drug-loaded nanoparticle and a preparation method and application thereof. The nanomedicine has good targeting and biocompatibility as well as serum stability and sustained release ability, can effectively knock down the target gene and enhance the killing effect on tumor cells.

[0008] The present invention is achieved in that:

[0009] In the first aspect, the present invention provides a breast cancer cell membrane-coated drug-loaded nanoparticle, which comprises a drug-loaded nanoparticle and a breast cancer cell membrane coated on the surface of the drug-loaded nanoparticle; the drug-loaded nanoparticle comprises a carrier and loaded with doxorubicin hydrochloride (DOX) and a nucleic acid sequence of shRNA targeting RecQ DNA helicase, and the carrier comprises polylactic acid-glycolic acid copolymer (PLGA).

[0010] Since PLGA particles as carriers and DOX treatment have their own defects, some specific receptors and adhesion molecules on the cell membrane can guide the cell membrane-coated nanoparticles to target specific parts. In order to improve the targeting and immune escape ability of the drug delivery system, the present invention uses breast cancer cell membranes to coat PLGA particles to obtain a bionic PLGA nanodrug. At the same time, the present invention uses RecQ DNA helicase as a therapeutic target for the first time, and uses the chemotherapy drug DOX and the gene-silencing RecQ DNA helicase for combined treatment to improve its anti-tumor effect, thereby providing new ideas and clues for the treatment of breast cancer.

[0011] In some embodiments, the RecQ DNA helicase is selected from any one of human RecQL1, BLM, WRN, RecQL4 and RecQL5.

[0012] In some embodiments, the RecQ DNA helicase is BLM.

[0013] Since BLM DNA helicase has tumor suppression function and is correlated with drug resistance in tumor treatment, the present invention uses BLM as a target and utilizes chemotherapy drug DOX in combination with gene silencing BLM for treatment to improve its anti-tumor effect.

[0014] In some embodiments, the nucleic acid sequence of the shRNA targeting the BLM gene is shown as SEQ ID NO.1.

[0015] By designing the nucleic acid sequence of shRNA targeting the BLM gene, and co-loading it with DOX on PLGA particles, and coating them with breast cancer cells, a new nano-delivery system is obtained. Experiments have shown that the nano-delivery system can effectively knock down the target gene and improve the killing effect on tumor cells. The experiments of the present invention can also provide a theoretical basis for the application of BLM as a therapeutic target in the treatment of breast cancer.

[0016] In some embodiments, the breast cancer cell membranes are derived from human MDA-MB-231 cells.

[0017] Some specific receptors and adhesion molecules on the cell membrane are used to guide the cell membrane-coated nanoparticles to target specific sites, such as Thomsen-Friedenreich antigen, Galectin-3, N-cadherin, epithelial cell adhesion molecule (EpCAM) and E-cadherin on the cancer cell membrane, which are very important for targeting tumors, homotypic tumor cells and adhesion. Based on this, the present invention utilizes a nano-delivery system that camouflages breast cancer cell membranes and co-loads DOX and shRNA targeting the BLM gene to improve the targeting and sustained-release capabilities of the nano-system.

[0018] In a second aspect, the present invention provides a method for preparing the above-mentioned breast cancer cell membrane-coated drug-loaded nanoparticles, which comprises: coating the breast cancer cell membrane on the surface of the drug-loaded nanoparticles by a co-extrusion method.

[0019] It should be noted that the method for preparing the above-mentioned breast cancer cell membrane-coated drug-loaded nanoparticles of the present invention includes but is not limited to the co-extrusion method, and can also be a nanoparticle precipitation method, a micro-controlled current method, etc., as long as the above-mentioned breast cancer cell membrane-coated drug-loaded nanoparticles can be prepared.

[0020] In some embodiments, the mass ratio of the drug-loaded nanoparticles to the breast cancer cell membrane is 1 to 3:1.

[0021] In some embodiments, the method for preparing breast cancer cell membrane-coated drug-loaded nanoparticles comprises mixing the drug-loaded nanoparticles with breast cancer cell membranes, standing at room temperature for 30 to 60 minutes, and repeatedly extruding with 800 nm and 400 nm polycarbonate membranes for 9 to 11 times.

[0022] In some embodiments, the preparation method of drug-loaded nanoparticles includes: dissolving PLGA in dichloromethane, dissolving DOX, shRNA-BLM plasmid and polyethyleneimine (PEI) in water, performing initial sonication to form a primary emulsion, then adding to a polyvinyl alcohol (PVA) aqueous solution, performing sonication again to form a secondary emulsion, adding an isopropanol aqueous solution to the secondary emulsion, stirring at room temperature to volatilize the dichloromethane, and collecting by centrifugation to obtain drug-loaded nanoparticles.

[0023] In some embodiments, the mass volume ratio of PLGA to dichloromethane is 15-25:1 (mg / mL).

[0024] In some embodiments, the mass volume ratio of DOX, shRNA-BLM plasmid and PEI to water is: 0.5-2:0.5-1.25:0.165-0.375:1.

[0025] In some embodiments, the volume ratio of the PLGA dichloromethane solution to the DOX / shRNA-BLM plasmid / PEI mixed system is 4-5:1.

[0026] In some embodiments, the concentration of PVA in the PVA aqueous solution is 1-2%, and the volume ratio of the primary emulsion to the PVA aqueous solution is 1:3-5.

[0027] In some embodiments, the concentration of isopropanol in the isopropanol aqueous solution is 1-4%, and the volume ratio of the double emulsion to the isopropanol aqueous solution is 1:2-3.

[0028] In some embodiments, the power of the first ultrasound is 30-60 W, the ultrasound time is 1-5 min, and the power of the second ultrasound is 60-100 W, the ultrasound time is 5-10 min.

[0029] In some embodiments, the stirring conditions are: a speed of 800-1000 rpm, a time of 12-24 h, and a centrifugal force of 14000×g.

[0030] In some embodiments, the mass ratio of PLGA, DOX, shRNA-BLM plasmid and PEI is: 10-12.5:0.25-1:0.1:0.03.

[0031] In a third aspect, the present invention also provides the use of the breast cancer cell membrane-coated drug-loaded nanoparticles or the breast cancer cell membrane-coated drug-loaded nanoparticles obtained by the above preparation method in the preparation of BLM-targeted anti-breast cancer drugs.

[0032] In some embodiments, the breast cancer comprises triple-negative breast cancer.

[0033] The present invention has the following beneficial effects:

[0034] The present invention is the first to use breast cancer cell membrane-coated nanoparticles that co-load doxorubicin hydrochloride and shRNA nucleic acid sequences targeting RecQ DNA helicase. The obtained breast cancer cell membrane-coated drug-loaded nanoparticles have good targeting and biocompatibility, serum stability and sustained release ability, effectively knock down target genes, and improve the killing effect on tumor cells. It has been verified that the above breast cancer cell membrane-coated drug-loaded nanoparticles can be used to treat triple-negative breast cancer and have high safety. Therefore, the breast cancer cell membrane-coated drug-loaded nanoparticles of the present invention have good medical transformation prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0036] Figure 1 TEM, particle size and potential map of the nanoparticles in Example 3;

[0037] Figure 2 The stability of the nanoparticles and the statistical graph of drug release in Example 3;

[0038] Figure 3 The Coomassie brilliant blue staining and protein immunoblotting images of the biomimetic membrane on the surface of the nanoparticles in Example 3;

[0039] Figure 4This is the laser confocal co-localization image of the MDA-MB-231 cell uptake experiment in Example 3;

[0040] Figure 5 This is the laser confocal co-localization image in Example 3;

[0041] Figure 6 The laser confocal image and flow cytometry statistical graph in Example 3;

[0042] Figure 7 The protein immunoblot and MTT statistical diagrams are the BLM protein silencing and killing effects of different nanoparticles in Example 3 on tumor cells;

[0043] Figure 8 This is a flow cytometry result diagram of the apoptosis-inducing effect of different nanoparticles on tumor cells in Example 3;

[0044] Fig. 9 This is a plate clone formation diagram of the detection of the ability of different nanoparticles in Example 3 to form tumor cell colonies;

[0045] Fig.10 This is the MTT statistical graph of empty-NPs and empty-NPs@231 in Example 3. DETAILED DESCRIPTION

[0046] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0047] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0048] Example 1

[0049] The present embodiment is a breast cancer cell membrane-coated drug-loaded nanoparticle, which includes a drug-loaded nanoparticle and an MDA-MB-231 cell membrane coated on the surface of the drug-loaded nanoparticle; the drug-loaded nanoparticle includes a carrier and a nucleic acid sequence of doxorubicin hydrochloride and shRNA targeting BLM loaded thereon, and the carrier is a polylactic acid-glycolic acid copolymer.

[0050] The weight ratio of the drug-loaded nanoparticles to the MDA-MB-231 cell membrane is 2:1, and the nucleic acid sequence of the shRNA targeting BLM is: GCCACATGTAGAAAGATAT (SEQ ID NO.1).

[0051] Example 2

[0052] This embodiment is a method for preparing breast cancer cell membrane-coated drug-loaded nanoparticles of embodiment 1, and the specific steps are as follows:

[0053] S1. Extraction of MDA-MB-231 cell membrane

[0054] A total of 10 bottles of MDA-MB-231 cells in T25 culture flasks were collected, and lysis buffer was added to the collected cell pellets and lysed overnight at 4°C. The buffer was 0.1×PBS, in which 1mM NaHCO3, 0.2mMTrypsin-EDTA and 1mM PMSF were added. The MDA-MB-231 cell suspension was ultrasonicated at 100W for 5min the next day. Centrifuge at 4°C and 800g for 10min, collect the supernatant, and centrifuge the supernatant at 4°C and 14,000g for 20min to collect the precipitate. Wash with PBS 3 times, resuspend with PBS, and store in a 4°C refrigerator.

[0055] S2. Preparation of PEI-shBLM NPs

[0056] The PEI solution and shRNA-BLM plasmid were mixed at a mass ratio of 0.3:1 and allowed to stand for 30 min before subsequent experiments.

[0057] Obtain shRNA-BLM plasmid:

[0058] Add 10 μL of shBLM bacterial solution to 5 mL of LB medium (containing Amp antibiotic concentration of 100 μg / mL), shake at 37°C and 200 rpm for 12 h, wait until the bacterial solution becomes turbid, add the above 5 mL of LB bacterial solution to 100 mL of LB medium (containing Amp antibiotic concentration of 100 μg / mL), shake at 37°C and 200 rpm for 6 h, then collect the bacteria by centrifugation at 8000g, and extract the shBLM plasmid using an endotoxin-free plasmid extraction kit.

[0059] S3. Preparation of shBLM / Dox co-loaded NPs cores by double emulsion solvent evaporation technique

[0060] (1) Add 1 mL of dichloromethane to the EP tube, accurately weigh 25 mg of PLGA and dissolve it in dichloromethane, use an ultrasonic probe to dissolve it, add 200 μL of sterile enzyme-free water (containing 2 mg DOX, 250 μg shBLM + 75 μg PEI) to the dissolved PLGA dichloromethane solution, use an ultrasonic cell disruptor at an ultrasonic amplitude of 30 W, sonicate for 3 seconds, stop for 3 seconds, and ultrasonically emulsify for 1 minute to form a W / O primary emulsion;

[0061] (2) The W / O primary emulsion was quickly poured into 3 mL of 2% PVA solution and ultrasonic emulsification was continued for 1 min to form a W / O / W secondary emulsion;

[0062] (3) The emulsion obtained in the previous step was added dropwise to 12 mL of sterile enzyme-free water, while using a magnetic stirrer; 320 μL of isopropanol solution was added dropwise to the double emulsion in the previous step, and then stirred with a magnetic stirrer at room temperature for 4-6 hours to evaporate the organic solvent such as dichloromethane as completely as possible;

[0063] (4) The above liquid was evenly divided into 1.5 mL EP tubes, centrifuged at 12000 g for 10 min, the supernatant was discarded, and the precipitate was collected;

[0064] (5) Add an appropriate amount of double distilled water to mix thoroughly, continue centrifugation under the above conditions, discard the supernatant, and repeat the washing three times; add 0.2 mL of double distilled water to the washed precipitate and mix well, place it in a vacuum freeze dryer and freeze-dry for about 24 hours to obtain lyophilized powder of PLGA nanoparticles; store the lyophilized powder in a 4°C refrigerator for later use.

[0065] S4. Preparation of MDA-MB-231 cell membrane-encapsulated PLGA nanoparticles loaded with shRNA and DOX

[0066] The prepared MDA-MB-231 cell membrane was extruded 11 times on an 800 nm polycarbonate membrane (Whatman) using an Avanti microextruder to prepare MDA-MB-231 cell membrane vesicles. The obtained MDA-MB-231 cell membrane vesicles were mixed with the prepared PLGA nanoparticles co-loaded with shRNA and DOX and passed through a 400 nm polycarbonate membrane and co-extruded 11 times to coat the cell membrane on the surface of the drug-loaded PLGA nanoparticle core.

[0067] Example 3

[0068] This example is the characterization of breast cancer cell membrane-encapsulated nanoparticles co-loaded with doxorubicin hydrochloride and shRNA-BLM plasmid obtained in Example 2

[0069] 1. Detection of particle size, potential and morphology of nanoparticles

[0070] 1. Particle size and potential measurement

[0071] 20 μL of the prepared nanoparticle mother solution was taken and added to 2 mL of ddH2O to mix well. The diluted solution was added to a quartz dish and the nanoparticle size, particle size distribution and potential were measured using a Malvern particle size / Zeta potential meter.

[0072] 2. Stability testing of nanoparticles

[0073] Appropriate amounts of shBLM / DOX-NPs and shBLM / DOX-NPs@231 were added to PBS buffer and FBS solution and stored at 4°C for one week. The particle size of the nanoparticles was detected every day, and its stability was evaluated by the change in particle size.

[0074] 3. Detection of in vitro release efficiency

[0075] Cut two 10cm sections from the dialysis bag, immerse them in distilled water and boil for 10-15min. After cooling, immerse the dialysis bag in distilled water and store at 4℃. Wear clean gloves to remove the dialysis bag, wash it with ultrapure water and remove bubbles, seal one side with a sealing clip, add equal amounts of shBLM / DOXNPs and shBLM / DOXnps@231 solutions to the two dialysis bags, and clamp the other side with a sealing clip. Check whether the dialysis bag is clamped to ensure that there is no leakage. Immerse the above four dialysis bags in release media with pH=5.0 and pH=7.4 respectively, place the bottle containing the dialysis bag in a constant temperature incubation shaker, and shake continuously at 37℃ away from light. Draw 1ml of dialysate at 2h, 4h, 6h, 8h, 12h, 18h, 24h, 36h, and 48h, and refill with an equal volume of dialysate. Measure the cumulative release of DOX with a UV spectrophotometer.

[0076] 4. Characterization of the morphology of nanoparticles using transmission electron microscope (TEM):

[0077] The sample was prepared according to the previous nanoparticle preparation, and 10 μL of nanoparticles (100 μg / mL) was added to the copper mesh for precipitation for 1 min. The upper floating liquid was removed with absorbent paper, and 10 μL of uranyl acetate negative stain was added to the mesh for precipitation for 1 min. The upper floating liquid was removed with absorbent paper, and the sample was left to dry at room temperature. The morphology, size, and dispersibility of the nanoparticles were observed under a transmission electron microscope and images were collected.

[0078] 5. SDS-PAGE protein electrophoresis detection

[0079] SDS-PAGE protein electrophoresis was used to detect the retention of membrane proteins on the surface of nanoparticles. The successful retention of MDA-MB-231 cell membrane proteins on the surface of nanoparticles is the key factor in achieving the biomimetic function of biomembrane-encapsulated nanoparticles.

[0080] Sample preparation: Proteins were extracted from MDA-MB-231 membrane, 231 membrane vesicles and shBLM / DOX-NPs@231, and the protein concentration was quantified using the BCA protein detection kit. 5X loading buffer was added to the supernatant and mixed, and then the mixture was boiled in 100°C water bath for 10 min. SDS-PAGE protein electrophoresis: SDS-PAGE gel was prepared according to the kit preparation method, installed in the electrophoresis tank, electrophoresis solution was added, the comb teeth were removed, samples were added to the wells, and electrophoresis was performed at 120V constant voltage for 90 min. The electrophoresed gel was placed in Coomassie brilliant blue dye solution for 2 h, then decolorized for 3 h, and observed and analyzed using a gel imaging system.

[0081] 6. Western Blot:

[0082] Following the SDS-PAGE step, the gel was transferred and blocked at 300mV constant current. The transfer time was set at 60-90min depending on the molecular weight of the target protein. Take out the PVDF membrane, place it in 5% skim milk powder in TBST blocking solution, and incubate it at room temperature for 1h on a decolorizing shaker. Antigen-antibody reaction: Add the diluted primary antibody and incubate overnight at 4℃. Aspirate the primary antibody and wash with TBST to remove unbound antibodies. Repeat 3 times, 10min each time. Aspirate TBST, add the diluted secondary antibody, and incubate it on a shaker at room temperature for 1 hour with slow shaking. Be careful not to get any light. Aspirate the secondary antibody and wash with TBST as described above; add the luminescent liquid and observe and analyze it with a gel imaging system.

[0083] 7. Test results

[0084] Figure 1 Figure 1 shows the transmission electron microscope, particle size and potential diagram of nanoparticles. A is the transmission electron microscope diagram, B is the particle size diagram, and C is the potential diagram. Figure 1 The shBLM / DOX-NPs, 231 cell membrane vesicles and shBLM / DOX-NPs@231 prepared in Example 2 were subjected to transmission electron microscopy scanning analysis and the particle size, particle size distribution and potential of shBLM / DOX-NPs and shBLM / DOX-NPs@231 were measured by Malvern particle size / Zeta potential meter. Figure 1 As shown, the results show that the nanoparticles are evenly dispersed without aggregation, and the membrane-coated nanoparticles have a typical membrane-core structure. Similarly, the particle size and potential results show that the particle size increases by 20nm after cancer cell membrane coating, and the potential also changes accordingly.

[0085] Figure 2 The stability of nanoparticles and the statistical diagram of drug release are shown in Figure 2. Figure 2 AB in the figure is the particle size stability of shBLM / DOX-PLGA and shBLM / DOX-PLGA@231 in PBS and 10% FBS at 37°C. Figure 2 CD in the figure is the release amount of shRNA and DOX from shBLM / DOX-PLGA and shBLM / DOX-PLGA@231 at pH 5.5 and 7.4 in vitro. Figure 2 As shown, in PBS at 37°C, the particle size of both naked nanoparticles and membrane-coated nanoparticles did not change significantly for at least 7 days, while in 10% serum, the size of naked nanoparticles increased from 200nm to about 400nm, while the particle size of cell membrane-coated nanoparticles was stable. This may be due to the protective effect of the cell membrane, which resists serum-induced aggregation. Tumor cells will change the pH of their microenvironment to acidic. The in vitro drug release results show that the nanoparticles can effectively release drugs in bursts and sustained release, and can release rapidly in an acidic environment.

[0086] Figure 3 Figure 1 is a Coomassie brilliant blue staining and protein immunoblotting diagram of the biomimetic membrane on the surface of the nanoparticles of this embodiment, wherein Figure A is a Coomassie brilliant blue staining diagram, and Figure BC is a protein immunoblotting diagram and its statistical diagram, as shown in Figure 1. Figure 3 As shown, the cancer cell membrane prepared in this example for nanoparticle coating was subjected to membrane-specific protein analysis, and the results showed that the cancer cell membrane successfully wrapped the nanoparticles, and that the protein molecules on the membrane surface were not changed by physical extrusion and ultrasonic treatment, and the membrane surface protein-specific molecules were retained.

[0087] Figure 4 This is the laser confocal co-localization image of the MDA-MB-231 cell uptake nanoparticle experiment of the present invention, the co-localization image of the DOX-NPs nucleus (red display) and the 231 cell membrane (green DiO dye display), the cell nucleus (DAPI blue), as shown in FIG. Figure 4 As shown in the results, the membrane-nuclear structure was further verified at the cellular level. The membrane of DOXnps@231 was stained with DiO dye. After cell engulfment, the confocal results showed that the membrane and nucleus existed in a co-localized image, indicating that the integrity of the nanoparticles can be maintained for a certain period of time after cell engulfment, proving that the cancer cell membrane was successfully wrapped.

[0088] 2. Further verification of the retention of the membrane-core structure of membrane-coated nanoparticles during cellular uptake

[0089] In order to study the integrity of the membrane-core structure of membrane-coated nanoparticles during cellular uptake, the cell membrane of DiO-labeled DOX-NPs@231 was incubated with MDA-MB-231 cells for 3 h, followed by fixation with 4% paraformaldehyde, addition of an anti-fluorescence quencher containing DOPI, and laser confocal imaging analysis.

[0090] 1. Laser confocal co-localization experiment:

[0091] Cell slides: add 100 μL of complete culture medium to a 6-well plate, place a sterile slide into the well, and gently press it with tweezers; inoculate MDA-MB-231 cells in the logarithmic growth phase into a 6-well plate containing cell slides; the next day, add PLGA-DOX / PEI-shBLM@231 and incubate for 24 hours; discard the culture medium, wash with PBS three times, add 1 mL of 4% paraformaldehyde, and fix at room temperature for 30 minutes; add 50 μL of anti-fluorescence quencher containing DOPI to the slide, gently cover the cell slide to avoid bubbles, let it stand for 10 minutes, and seal it with a sealing agent. Take photos under laser confocal microscope for observation.

[0092] Figure 5 This is the laser confocal co-localization image of the present invention, shBLM (shown in green), DOX (shown in red), cell nucleus (shown in blue by DAPI), and laser confocal observation shows that shBLM / DOX-NPs@231 nanoparticles achieve co-delivery of shRNA and DOX.

[0093] 2. Confocal laser scanning to qualitatively observe cell uptake

[0094] DOX-NPs and DOX-NPs@231 were co-cultured with MDA-MB-231 cells, MCF-10A cells, LO2 cells, and RAW264.7 cells for 3 h. The culture medium was discarded, and the cells were gently washed with PBS three times. After fixation and staining, the cells were observed and photographed under an inverted laser confocal microscope.

[0095] 3. Quantitative observation of cellular uptake by flow cytometry

[0096] DOX-NPs and DOX-NPs@231 were co-cultured with MDA-MB-231 cells, MCF-10A cells, LO2 cells, and RAW264.7 cells for 3 h. The cells were digested with trypsin, washed three times with PBS, and fixed with 4% paraformaldehyde. The fluorescence intensity was observed using the PI-A channel of a flow cytometer, and the median fluorescence intensity of each group was recorded and counted.

[0097] Figure 6 The laser confocal images and flow cytometry statistical graphs of the present invention are shown in Figure AB, where Figure AB is a laser confocal image and its fluorescence intensity statistical graph, DOX (red display), cell nucleus (DAPI blue display), Figure CD is a flow cytometry fluorescence intensity histogram and its median fluorescence intensity (MFI) statistical graph, the results are as follows Figure 6As shown, compared with DOX-NPs, the DOX fluorescence intensity of MDA-MB-231 cells co-incubated with DOX-NPs@231 increased through laser confocal observation, while the fluorescence intensity in other cells weakened. At the same time, flow cytometry results also showed that the fluorescence intensity of MDA-MB-231 cells co-incubated with DOX-NPs@231 increased by 3.3 times, while the fluorescence of other cells weakened. The results confirmed that cancer cell membrane-wrapped nanoparticles have certain cell selectivity compared with naked nanoparticles.

[0098] 4. Detection of silencing efficiency of nanoparticles: same as western blot method

[0099] Cell killing effect of nanoparticles (MTT method): MDA-MB-231 cells in the logarithmic growth phase were removed, digested with trypsin, and inoculated into 96-well plates at 8,000 cells / well for overnight culture. The original culture medium was discarded, and Control, free DOX, DOX-NPs, shNC / DOX-NPs, shBLM / DOX-NPs, shNC / DOX-NPs@231, shBLM / DOX-NPs@231, LP2000-shNC, LP2000-shBLM were added, and 3 replicates were set up, with blank group and negative control group. After 48 hours of culture, add 10 μL of 5 mg / mL MTT solution, continue to culture for 4 hours, and aspirate the culture medium with excess MTT solution in the well; add 150 μL of DMSO to dissolve MTT, place on a shaker at 150 rpm, and shake for 10 minutes; put in an ELISA reader, select a wavelength of 490 nm, and detect the absorbance value in each well;

[0100] The relative cell survival rate and relative inhibition rate were calculated based on the obtained OD values. The formula is as follows:

[0101] Survival rate = average OD value of experimental group / average OD value of control group × 100%

[0102] Inhibition rate = (average OD value of control group - average OD value of experimental group) / average OD value of control group × 100%.

[0103] Figure 7 The protein immunoblot images and MTT statistical graphs of the BLM protein silencing effect and killing effect of different nanoparticles of the present invention on tumor cells are shown in Figure A, and Figure B is an MTT statistical graph. The results are shown in Figure 1. Figure 7 As shown, the results showed that co-loaded DOX and shBLM nanoparticles could stably silence the BLM protein expression of MDA-MB-231 cells. Cytotoxicity experiments showed that compared with single drugs, co-loaded DOX and shBLM nanoparticles better inhibited tumor cell proliferation.

[0104] 5. Detection of Cell Apoptosis by Flow Cytometry

[0105] MDA-MB-231 cells in the logarithmic growth phase were plated in a six-well plate with a cell confluence of about 50% and cultured overnight; Control, free DOX, shBLM-NPs, DOX-NPs, DOX-NPs@231, shNC / DOX-NPs, shBLM / DOX-NPs, shNC / DOX-NPs@231, and shBLM / DOX-NPs@231 were added and cultured for 48 hours; the cells were digested and collected with EDTA-free 0.25% trypsin, 5 μL of Annexin V-APC and 10 μL of 7-AAD were added to each tube and incubated for 5 minutes. After the incubation, the cells were detected by flow cytometry within 1 hour.

[0106] Figure 8 Figure 2 is a flow cytometry result diagram of the apoptosis-inducing effect of different nanoparticles of the present invention on tumor cells. Figure 8 As shown, the shBLM / DOX-NPs group and the shBLM / DOX-NPs@231 group can more strongly increase the apoptosis of tumor cells induced by DOX; compared with single drugs, DOX and shBLM nanoparticles co-loaded on cancer cell membranes can increase the apoptosis of tumor cells induced by DOX.

[0107] 6. Colony formation assay

[0108] Take the MDA-MB-231 cells in the logarithmic growth phase, lay them in a six-well plate, the cell number is 800, and culture them overnight; add Control, free DOX, shBLM-NPs, DOX-NPs, shNC / DOX-NPs, shBLM / DOX-NPs, shNC / DOX-NPs@231, shBLM / DOX-NPs@231 and culture them, and change the medium every 72 hours. After 10 days, fix the cells with 4% paraformaldehyde for 30 minutes, stain with the prepared 0.1% crystal violet for 10 minutes, wash and take pictures.

[0109] Fig. 9 The plate clone formation diagram of the different nanoparticles of the present invention for detecting the ability of tumor cell colony formation is shown in FIG. Fig. 9 As shown, the shBLM / DOX-NPs group and the shBLM / DOX-NPs@231 group can more strongly inhibit the tumor cell clone formation ability, and the co-loaded DOX and shBLM nanoparticles have stronger ability to inhibit tumor cell clone formation than single drugs.

[0110] 7. In vitro safety assessment of nanoparticles

[0111] MDA-MB-231 cells with good growth status were seeded in 96-well plates, with 1×104 Cells were cultured overnight. Different contents of empty-NPs nanoparticles and empty-NPs@231 nanoparticles (0, 100, 200, 300, 400, 500, 600 μg) were co-cultured with MDA-MB-231 cells for 24 h and 48 h. After the culture, 10 μL of 5 mg / mL MTT solution was added, and the culture was continued for 4 h. The culture medium with excess MTT solution in the well was aspirated; 150 μL of DMSO was added to dissolve MTT, and the well was placed on a shaker at 150 rpm for 10 min. The well was placed in an ELISA reader, and the wavelength was selected at 490 nm. The absorbance value in each well was detected, and the relative cell survival rate and relative inhibition rate were calculated based on the obtained OD value.

[0112] Fig.10 The MTT statistical graphs of the empty-NPs and empty-NPs@231 of the present invention are shown in Figure A, where Figure B is the MTT statistical graph after 24h of co-incubation, Figure C is the MTT statistical graph after 48h of co-incubation, and the results are shown in Figure 5. Fig.10 As shown, at 24 h, as the concentration of empty-NPs and empty-NPs@231 increased, no toxic side effects were observed on MDA-MB-231 cells. Even at 72 h, when the concentration reached 600 μg / mL, no cytotoxic effect was observed on MDA-MB-231 cells, indicating that the prepared nanoparticles have high biosafety.

[0113] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A breast cancer cell membrane-coated drug-loaded nanoparticle, characterized in that: include: Drug-loaded nanoparticles, and breast cancer cell membranes coated on the surfaces of the drug-loaded nanoparticles; The drug-loaded nanoparticles include a carrier and loaded doxorubicin hydrochloride and a nucleic acid sequence of shRNA targeting human RecQ DNA helicase; The carrier includes poly(lactic acid-glycolic acid) copolymer.

2. The breast cancer cell membrane-coated drug-loaded nanoparticles according to claim 1, characterized in that: The RecQ DNA helicase is selected from any one of human RecQL1, BLM, WRN, RecQL4 and RecQL5; Preferably, the RecQ DNA helicase is BLM.

3. The breast cancer cell membrane-coated drug-loaded nanoparticles according to claim 2, characterized in that: The nucleic acid sequence of the shRNA targeting the BLM gene is shown in SEQ ID NO.

1.

4. The breast cancer cell membrane-coated drug-loaded nanoparticles according to claim 1, characterized in that: The breast cancer cell membrane is derived from human MDA-MB-231 cells.

5. The method for preparing breast cancer cell membrane-coated drug-loaded nanoparticles according to any one of claims 1 to 4, characterized in that: The breast cancer cell membrane is coated on the surface of the drug-loaded nanoparticles by a co-extrusion method.

6. The preparation method according to claim 5, characterized in that: The mass ratio of the drug-loaded nanoparticles to the breast cancer cell membrane is 1 to 3:1; Preferably, the preparation method comprises mixing the drug-loaded nanoparticles with breast cancer cell membranes, leaving the mixture to stand at room temperature for 30 to 60 minutes, and repeatedly extruding the mixture 9 to 11 times using 800 nm and 400 nm polycarbonate membranes in sequence.

7. The preparation method according to claim 5, characterized in that: The preparation method of the drug-loaded nanoparticles comprises: The polylactic acid-glycolic acid copolymer is dissolved in dichloromethane, doxorubicin hydrochloride, shRNA-BLM plasmid and polyethyleneimine are dissolved in water, and a primary emulsion is formed by ultrasonication for the first time, and then added to a polyvinyl alcohol aqueous solution, and ultrasonication is performed again to form a double emulsion, and an isopropanol aqueous solution is added to the double emulsion, and the dichloromethane is volatilized by stirring at room temperature, and the drug-loaded nanoparticles are obtained by centrifugation. Preferably, the mass volume ratio of the polylactic acid-glycolic acid copolymer to dichloromethane is 15-25:1 (mg / mL); Preferably, the mass volume ratio of doxorubicin hydrochloride, shRNA-BLM plasmid and polyethyleneimine to water is: 0.5-2:0.5-1.25:0.165-0.375:1 (mg / mL); Preferably, the volume ratio of the dichloromethane solution of the polylactic acid-glycolic acid copolymer to the mixed system of doxorubicin hydrochloride / shRNA-BLM plasmid / polyethyleneimine is 4-5:1; Preferably, the mass concentration of polyvinyl alcohol in the polyvinyl alcohol aqueous solution is 1-2%, and the volume ratio of the primary emulsion to the polyvinyl alcohol aqueous solution is 1:3-5; Preferably, the mass concentration of isopropanol in the isopropanol aqueous solution is 1-4%, and the volume ratio of the double emulsion to the isopropanol aqueous solution is 1:2-3; Preferably, the power of the first ultrasound is 30-60W, the ultrasound time is 1-5min, and the power of the second ultrasound is 60-100W, the ultrasound time is 5-10min; Preferably, the stirring conditions are: a speed of 800 to 1000 rpm, a time of 12 to 24 h, and a centrifugal force of 14000×g.

8. The preparation method according to claim 7, characterized in that: The mass ratio of the polylactic acid-glycolic acid copolymer, doxorubicin hydrochloride, shRNA-BLM plasmid and polyethyleneimine is: 10-12.5:0.25-1:0.1:0.

03.

9. Use of the breast cancer cell membrane-coated drug-loaded nanoparticles according to any one of claims 1 to 4 or the breast cancer cell membrane-coated drug-loaded nanoparticles obtained by the preparation method according to any one of claims 5 to 8 in the preparation of BLM-targeted anti-breast cancer drugs.

10. The use according to claim 9, characterized in that: The breast cancer includes triple-negative breast cancer.